series-b
Stage
2
Investors
About
NeuroTherapia is a clinical-stage biotechnology company focused on developing oral small-molecule therapies targeting neuroinflammation for neurological and neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and neuropathic pain. Its lead product, NTRX-07, is a highly selective cannabinoid type 2 (CB2) receptor agonist designed to reduce neuroinflammation and promote neuronal survival.
Explore NeuroTherapia's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.